Abstract
COVID-19 is associated with increased risks for mood or anxiety disorders, but it remains uncertain how the association evolves over time or which patient groups are most affected. We conducted a retrospective cohort study using a nationwide database of electronic health records to determine the risk of depressive or anxiety disorder diagnoses after SARS-CoV-2 infection by 3-month blocks from January 2020 to April 2022. The study population comprised 822,756 patients (51.8% female; mean age 42.8 years) with COVID-19 and 2,034,353 patients with other respiratory tract infections (RTIs) (53.5% female, mean age 30.6 years). First time diagnoses of depressive or anxiety disorders 14 days to 3 months after infection, as well as new or new plus recurrent prescriptions of antidepressants or anxiolytics, were compared between propensity score matched cohorts using Kaplan-Meier survival analysis, including hazard ratio (HR) and 95% confidence interval (CI). Risk of a new diagnosis or prescription was also stratified by age, sex, and race to better characterize which groups were most affected. In the first three months of the pandemic, patients infected with SARS-CoV-2 had significantly increased risk of depression or anxiety disorder diagnosis (HR 1.65 [95% CI, 1.30-2.08]). October 2021 to January 2022 (HR, 1.12 [95% CI, 1.06–1.18]) and January to April 2022 (HR, 1.08 [95% CI, 1.01–1.14]). Similar temporal patterns were observed for antidepressant and anxiolytic prescriptions, when the control group was patients with bone fracture, when anxiety and depressive disorders were considered separately, when recurrent depressive disorder was tested, and when the test period was extended to 6 months. COVID-19 patients ≥65 years old demonstrated greatest absolute risk at the start of the pandemic (6.8%), which remained consistently higher throughout the study period (HR, 1.20 [95% CI, 1.13–1.27]), and overall, women with COVID-19 had greater risk than men (HR 1.35 [95% CI 1.30–1.40]).
Similar content being viewed by others
Introduction
Reports of increased mood and anxiety disorders during the COVID-19 pandemic raised interest in the mental health impact of COVID-19. The World Health Organization reported a 27.6% increase in depression and a 25.6% increase in anxiety in 2020 compared to 2019 [1], and the Centers for Disease Control and Prevention reported significant increases in anxiety and depression from August 2020 to February 2021 [2]. Some studies have suggested that this increase may be due to a direct association between COVID-19 infection and psychiatric sequelae [3,4,5,29, 30]. We accounted for this by comparing patients hospitalized with COVID-19 with patients hospitalized with other respiratory infections and found a similar temporal pattern of risk and observed the same pattern. In addition, undiagnosed or undocumented SARS-CoV-2 infections in the control cohorts undoubtedly increased during the pandemic, which could produce a decrease in HRs if COVID-19 itself is indeed a risk for subsequent anxiety and depression. Our study partially accounted for this by excluding positive antibody test results for SARS-CoV-2 before December 11, 2020, within the control cohorts to capture natural infection before vaccines were introduced. Additionally, if increasing undetected COVID-19 infections occurred in the control cohort and such infection was driving the outcome, we would expect to see an associated rise in the proportion of control patients who developed a depressive or anxiety disorder, which was not the case. Another explanation we considered was bias of ascertainment, or the possibility that COVID-19 patients received more medical follow-up and thus more opportunities for a mood or anxiety disorder to be detected, leading to elevated HRs. Indeed, COVID-19 patients had a greater number of follow-up visits on average throughout the study period, even when the HR was not significantly elevated. If increased follow-up among COVID-19 patients was responsible for elevated HRs, we would expect excess hazard to be present throughout the entire study period. Additionally, analyses comparing COVID-19 patients to bone fracture patients, a group that also requires follow-up, revealed similar temporal patterns.
Our results on risk stratified by age show a consistent elevation in older patients. While higher rates of anxiety and depressive symptoms have been reported among younger adults during the pandemic [8, 9, 31, 32] and were emphasized in the lay press, our study found older adults to be at increased absolute risk, contributing to a growing body of literature pointing to inconsistencies in the reported prevalence of mood and anxiety disorders in the elderly [33, 34]. Many factors could account for this excess risk of anxiety and depression in the elderly during the pandemic. The risk of death or hospitalization following COVID-19 was greater in the elderly even after vaccines and antiviral drugs became available, since breakthrough infections and incomplete treatment responses were more common. Thus, fear may have persisted in older patients. Older adults also may have been disproportionately affected by social distancing guidelines, leading to increased social isolation, inadequate care at long-term care facilities, and loss of home care [35,36,37] Additionally, there were undoubtedly greater disruptions in social networks of older individuals as peers and loved ones passed away. All these considerations might contribute to the increased risk for anxiety and depression among older adults. The elderly may also have had more severe COVID-19 infections and/or had more underlying medical conditions that produced contact with the health care system, presenting greater opportunity for mental health issues to be diagnosed and treated. While this has been largely accounted for by matching for medical risk factors for severe COVID-19 disease and critical care services as well as conducting sensitivity analyses on hospitalized patients, it is still possible that this bias accounts for a portion of our results.
Our results stratified by sex support reports of higher depressive and anxiety disorders in females [38, 39]. Women traditionally assume an excess of the caregiving burden, which increased during the pandemic as schools closed and home help was unavailable. Especially early in the pandemic, job and financial security were reduced, and domestic violence increased during lockdown. Moreover, men may be more reluctant to seek help [40]. Our study found no consistent difference in risk after COVID-19 or other RTI when stratified by race; a slight but significant reduction in hazard was evident when comparing Black patients to White patients, although previous studies indicated that racial minorities experienced greater declines in mental health during the pandemic due to factors such as decreased access to mental health services, higher rates of job loss, and collective trauma from instances of violence in communities of color [41,42,43]. It is possible that mental distress among communities of color did not lead to physician contact to the same extent that as in white communities, resulting in fewer diagnoses in the electronic health record [43].
Limitations of our study include our inability to determine causality due to its retrospective, observational design. In addition, despite the very large number of electronic records included in the study, sample sizes were too small to properly evaluate racial and intersectional subgroups that might be predicted to have special vulnerability, such as women of childbearing age or women of color. Our study does not cover patients who did not have contact with the health care system, nor is the population necessarily representative of the entire US population. Moreover, EHR data may not have captured all COVID-19 infections, especially later in the pandemic as home testing became more prevalent, and vaccination status is likely underreported in the TriNetX Analytics Platform as vaccine availability expanded outside of the health systems. These potential omissions may have impacted propensity score matching and precluded testing the impact of vaccination on mental health outcomes. It is important to recognize that recurrence of depressive or anxiety disorders, especially if prior episodes were remote, is difficult to assess in the electronic health record but could represent an important risk factor for new episodes. In fact, when both new and recurrent prescriptions for antidepressants and anxiolytics were analyzed, the number of patients doubled compared to first-time prescriptions. Other than recurrent major depressive disorder (F33), we did not measure the association between COVID-19 and individual ICD-10 codes within the depressive and anxiety disorder subgroups. However, we did attempt to capture exacerbations of depressive and anxiety disorders by assessing prescriptions among patients who had not had prescriptions for these medications during the previous year. Anxiolytic drugs may have been prescribed for problems other than anxiety, such as sleep aids, and antidepressants may have been prescribed for indications other than depression, such as adjunctive pain therapy. However, the consistency of findings using the ICD-10 diagnostic categories and the pharmacologic interventions used most to treat them suggest that they are largely concordant measures for similar medical issues. Finally, although other RTIs and bone fractures were chosen as control health events to compare with COVID-19 infection, these diagnoses are not necessarily free of psychiatric risk. Both could also be linked to psychiatric sequelae through physiologic mechanisms, such as causing systemic inflammation that impacts the brain, or psychological mechanisms, such as limiting mobility and quality of life.
Overall, our findings, derived from a very large population, suggest that while a COVID-19 diagnosis was associated with elevated risk of depressive and anxiety disorders compared to control health events at the start of the pandemic, this risk decreased or was only mildly elevated after the first three months of the pandemic. It is likely that these temporal trends can be largely explained by the social context of the pandemic rather than, or in addition to, pathophysiologic mechanisms. Moreover, in our population, elderly patients were at particular risk throughout the duration of the pandemic. Recent USPSTF guidelines recommend screening for adults over 65 years old, but with only a “B” level of evidence for depression and insufficient evidence for anxiety [44, 45]. Our results indicate that more work is needed to improve the utility of screening instruments for older patients, especially since major public health challenges, ongoing, renewed, or new, are likely to continue. Additional research that captures patients without regular contact with the health system and patients from other racial and ethnic populations and in special communities such as the LGBTQ+ community is necessary to better understand the association between COVID-19 infection and mental health disorders and to identify those that may require continued screening.
Data availability
The data analyzed in this paper cannot be made available because we used a cloud-based database and cannot download the data set. This database is constantly being upgraded with new information, so the actual data from which the analysis was done will not be available at a subsequent time. That is why we indicate when the database was accessed, which specific data set was used, and the specifications for each cohort and analysis (either in the supplemental materials or in the main paper). Using these parameters, the study can then be repeated in the updated data set. The EMR data is deidentified and so individual data cannot be made available to us or anyone else.
References
World Health Organization. Mental Health and COVID-19: Early evidence of the pandemic’s impact: Scientific brief, 2 March 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1. Accessed 11 Mar 2023.
Vahratian A, Blumberg SJ, Terlizzi EP, Schiller JS. Symptoms of anxiety or depressive disorder and use of mental health care among adults during the COVID-19 pandemic—United States, August 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70:490–4.
Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigottt DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700–12.
Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130–40.
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27.
**e Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with COVID-19: cohort study. BMJ. 2022;376. https://doi.org/10.1136/bmj-2021-068993.
Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic in 2020. J Affect Disord. 2022;296:567–76.
Shuster A, O’Brien M, Luo Y, Berner LA, Perl O, Heflin M, et al. Emotional adaptation during a crisis: decline in anxiety and depression after the initial weeks of COVID-19 in the United States. Transl Psychiatry. 2021;11:435.
Daly M, Robinson E. Psychological distress and adaptation to the COVID-19 crisis in the United States. J Psychiatr Res. 2021;136:603–9.
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html. Accessed 26 Jun 2023.
Gomez JMD, Du-Fay-de-Lavallaz JM, Fugar S, Sarau J, Simmons JA, Clark B, et al. Sex Differences in COVID-19 Hospitalization and Mortality. J Women’s Health (Larchmt). 2021;30:646–53.
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html. Accessed 26 Jun 2023.
Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: Information for healthcare professionals. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html#print. Accessed 4 Mar 2023.
Fancourt D, Steptoe A, Bu F. Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study. Lancet Psychiatry. 2021;8:141–9.
Olaker VR, Kendall EK, Wang CX, Parran TV, Terebuh P, Kaleber DC, et al. Association of Recent SARS-CoV-2 Infection With New-Onset Alcohol Use Disorder, January 2020 Through January 2022. JAMA Netw Open. 2023;6:e2255496.
Centers for Disease Control and Prevention. CDC updates and shortens recommended isolation and quarantine period for general population. https://www.cdc.gov/media/releases/2021/s1227-isolation-quarantine-guidance.html. Accessed 4 Mar 2023.
Perez-Arce F, Angrisani M, Bennett D, Darling J, Kapteyn A, Thomas K, et al. COVID-19 vaccines and mental distress. PLoS One. 2021;16:e0256406.
Chen S, Aruldass AR, Cardinal RN. Mental health outcomes after SARS-CoV-2 vaccination in the United States: a national cross-sectional study. J Affect Disord. 2022;298:396–9.
Anderson J, Fingerhut H. COVID anxiety rising amid delta surge, AP-NORC poll finds. AP News. Published 2021. https://apnews.com/article/lifestyle-business-health-travel-coronavirus-pandemic-27bf20514cd3da917c54bf71a41f2e8e. Accessed 4 Mar 2023.
Galatzer-Levy IR, Huang SH, Bonanno GA. Trajectories of resilience and dysfunction following potential trauma: a review and statistical evaluation. Clin Psychol Rev. 2018;63:41–55.
Daly M, Robinson E. Depression and anxiety during COVID-19. Lancet. 2022;399:518.
Chen S, Bonanno GA. Psychological adjustment during the global outbreak of COVID-19: a resilience perspective. Psychol Trauma. 2020;12:S51–S54.
Lancee WJ, Maunder RG, Goldbloom DS. Prevalence of psychiatric disorders among Toronto hospital workers one to two years after the SARS outbreak. Psychiatr Serv. 2008;59:91–95.
Bonanno GA, Ho SM, Chan JC, Kwong RSY, Cheung CKY, Wong CPY, et al. Psychological resilience and dysfunction among hospitalized survivors of the SARS epidemic in Hong Kong: a latent class approach. Health Psychol. 2008;27:659–67.
Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329:1934–46.
Callard F, Perego E. How and why patients made long Covid. Soc Sci Med. 2021;268:113426.
Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21:361–79.
Chokkalingam AP, Hayden J, Goldman JD, Li H, Asubonteng J, Mozaffri E, et al. Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States. JAMA Netw Open 2022;5:e2244505.
Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilian FC, et al. Impact of COVID-19 vaccination on the risk of develo** long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine 2022;53:101624.
Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin Infect Dis. 2021;73:2257–64.
Varma P, Junge M, Meaklim H, Jackson ML. Younger people are more vulnerable to stress, anxiety and depression during COVID-19 pandemic: a global cross-sectional survey. Prog Neuro-Psychopharmacol Biol Psychiatry 2021;109:110236.
Zhu C, Zhang T, Li Q, Chen X, Wang K. Depression and anxiety during the COVID-19 pandemic: epidemiology, mechanism, and treatment. Neurosci Bull 2023;39:675–84.
Andreas S, Schulz H, Volkert J, Dehoust M, Sehner S, Suling A, et al. Prevalence of mental disorders in elderly people: the European MentDis_ICF65 study. Br J Psychiatry. 2017;210:125–31.
Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin Psychol. 2009;5:363–89.
Andreescu C, Lenze E, Lavretsky H. Is anxiety in late life an uncharted territory?—questioning the USPSTF draft recommendation statement for anxiety screening in older adults. JAMA Psychiatry. 2023;80:197–8.
Hadjistavropoulos T, Asmundson GJG. COVID stress in older adults: considerations during the Omicron wave and beyond. J Anxiety Disord. 2022;86:102535.
United Nations. Policy Brief: The Impact of COVID-19 on older persons. https://unsdg.un.org/sites/default/files/2020-05/Policy-Brief-The-Impact-of-COVID-19-on-Older-Persons.pdf. Accessed 4 Mar 2023.
Metin A, Erbiçer ES, Şen S, Çetinkaya A. Gender and COVID-19 related fear and anxiety: a meta-analysis. J Affect Disord. 2022;310:384–95.
Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020;66:504–11.
Addis M, Mahalik J. Men, masculinity, and the contexts of help seeking. Am Psychol. 2003;58:5–14.
Thomeer MB, Moody MD, Yahirun J. Racial and ethnic disparities in mental health and mental health care during the COVID-19 pandemic. J Racial Ethn Health Disparities. 2023;10:961–76.
Nguyen LH, Anyane-Yeboa A, Klaser K, Merina A, Drew DA, Ma W, et al. The mental health burden of racial and ethnic minorities during the COVID-19 pandemic. PLOS One. 2022;17:e0271661.
Panchal N, Saunders H, Ndugga N. Five Key Findings on Mental Health and Substance Use Disorders by Race/Ethnicity. KFF. Published 2022. https://www.kff.org/racial-equity-and-health-policy/issue-brief/five-key-findings-on-mental-health-and-substance-use-disorders-by-race-ethnicity/. Accessed 4 Mar 2023.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults. Accessed 22 Jun 2023.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening. Accessed 22 Jun 2023.
Acknowledgements
This project was supported by the National Institutes of Health, National Institute on Alcohol. Abuse and Alcoholism award R01AA029831-01 and the National Institute on Aging R01AG076649 and by the Clinical and Translational Science Collaborative of Cleveland, which is funded by the National Institutes of Health, National Center for Clinical and Translational Science, Clinical and Translational Science Award UL1TR002548. We gratefully acknowledge Lindsey Wang, Center for Artificial Intelligence and Drug Discovery, Case Western Reserve University, for the creation of figures. She was not compensated for her contributions. The funders have no roles in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Contributions
RX, PBD, and CXW conceived and designed the study and edited the manuscript. PT took a major role in advising CXW and editing the manuscript. CXW performed the initial analyses, wrote the initial and subsequent drafts of the manuscript, and prepared the tables and material for the figures. She has had full access to all the data. RK performed some of the analyses. VRO and PT performed some of the analyses and advised on the construction of the cohorts for the analysis. RX and PBD provided support for the study. DCK provided access to TriNetX, advice on analytics, and edited the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, C.X., Kohli, R., Olaker, V.R. et al. Risk for diagnosis or treatment of mood or anxiety disorders in adults after SARS-CoV-2 infection, 2020–2022. Mol Psychiatry 29, 1350–1360 (2024). https://doi.org/10.1038/s41380-024-02414-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-024-02414-x
- Springer Nature Limited